Medtronic is on track to increase its quarterly dividend for the 48th consecutive year, with a raise expected in the coming months. The company’s board has signaled its intent to sustain this legacy, reflecting confidence in Medtronic’s durable cash flows. In fiscal 2025 the company generated approximately $6.2 billion in free cash flow, covering dividend payments with a payout ratio near 50 percent. Investors view the accelerated payout history as a sign of Medtronic’s commitment to returning capital even as it invests in new growth initiatives.

Medtronic’s Pulsed Field Ablation (PFA) franchise delivered revenue growth of 25 percent year-over-year in calendar 2025, driven by capital sales in Europe and initial U.S. roll-outs. The Symplicity renal denervation business saw a 30 percent revenue increase, supported by expanded reimbursement coverage and new clinical data. These high-growth franchises helped offset modest declines in legacy cardiac rhythm management products. Medtronic maintains an A credit rating from S&P with a stable outlook, underpinned by a debt/EBITDA ratio of approximately 2.5× and strong operating margins near 35 percent. The balance sheet flexibility positions the company to fund tuck-in acquisitions while preserving its dividend policy.